Another healthcare company is leveraging AI to address the new coronavirus pandemic and help identify potential patients who could have the virus. Persivia, a company that provides bundled payment, value-based care, population health and quality management solutions, launched its new COVID-19 surveillance model through its Solition AI engine on its CareSpace platform.
Persivia partners with hospitals and practices to manage value-based care programs, quality, care and risk within inpatient and ambulatory environments, while its bundled payment solutions platform can follow a patient from hospital admission through at-home care. It also helps healthcare organizations manage fee-for-service care programs and others payment models.
The Solition module processes structured and unstructured data across disparate sources, including EHR data, to target suspected COVID-19 cases. The module is powered by an AI engine that uses evidence-based algorithms to identify potential COVID-19 cases in the data.
The launch of the module comes at a time when COVID-19 testing in the U.S. still lags far behind that of other countries, potentially limiting awareness of the number of cases in the nation and causing a lag in monitoring the virus’ progression.
The potential cases in the Solition module are grouped into levels of alerts that medical professionals can search for patients based on alert level and symptoms. The level one alert includes people who have three or more relevant symptoms of the virus, such as fever, cough and shortness of breath. Those with other risks, such as recent travel history or exposure, are considered to a level two alert. At level one, patients’ physicians are prompted to monitor them, while level two patients are recommended to get a CDC test for the virus. Level three alerts are for patients who are presumed to have COVID-19, while level four alerts correspond with patients who have been confirmed to have the virus.
“The inability to match the documentation of travel history in the intake nurse’s notes with the symptoms coded by the physician was a flaw––one we have bridged with our ability to create evidence-based ruleset within CareSpace,” said Persivia Chief Medical Officer Fauzia Khan, MD. “CareSpace is built to acquire, aggregate, and normalize data from multiple sources which ensures it doesn’t miss any piece of recorded information about a patient from anywhere along the care continuum. This is critical when it comes to public health threats. We hope our ruleset will help healthcare organizations across the country identify the novel coronavirus in patients more quickly and effectively, leading to more appropriate testing, timely care, and better health outcomes.”
Persivia, based in Marlborough, Massachusetts, raised $15 million in a Series C funding round late last year, according to TechCrunch, with Petrichor Healthcare Capital Management listed as the lead investor.
The company brought the ruleset to production on its modular AI system within 10 days and will adapt and add to it as more information about the disease becomes available. Rulesets can be developed and added for any health states, as well as other infectious diseases and behavioral health or heart failure.